Research finds therapy may slow kidney damage from type 2 diabetes
Researchers in Galway have found that a stem cell therapy called ORBCEL-M can slow kidney function loss in patients with type 2 diabetes. The clinical trial results suggest a potential new treatment path for chronic kidney disease.
Why it matters
This medical breakthrough could significantly improve quality of life and reduce the need for dialysis for millions of diabetic patients.
Researchers in Galway have revealed new evidence that a single stem cell therapy treatment can slow the loss of kidney function in adults who have diabetic kidney disease.
The stem cell therapy, ORBCEL-M, was developed by University of Galway spinout company, Orbsen Therapeutics,
The new results come from the EU Horizon 2020-funded NEPHSTROM project, which conducted a clinical trial of this therapy as an intravenous infusion in adults with progressive chronic kidney disease due to type 2 diabetes.
The early-stage trial involved two groups of patients treated with lower and higher doses of ORBCEL-M as well as a group treated with a placebo infusion.
The results for these groups confirmed that a single dose of ORBCEL-M was as safe as the placebo infusion and associated with better preservation of kidney function. Patients taking part in the trial were followed closely for 18 months after receiving the therapy.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in